

Learning Objectives

After completing this activity, the participant should be better able to:

- Describe the current status of chemotherapy for colorectal cancer with BRAF and other mutations
- Appraise the importance of the emerging role of RAS mutations in patients undergoing resection of colorectal liver metastases
- Explain the data on utilization of alternate angiogenesis inhibitors in colorectal cancer and the role of all-RAS wild-type mutation status
- Describe the role of EGFR inhibitors in combination with chemotherapy in patients with KRAS and other mutations
- Explain the data on utilization of alternate angiogenesis inhibitors in colorectal cancer
- Explain the multidisciplinary approaches in the management of rectal cancer
- Describe the radiation therapy options for rectal and non-colorectal gastrointestinal cancers
- Describe current treatment options for the management of hepatocellular carcinoma
- Identify advances in the treatment of esophagogastric carcinoma
- Identify advances in the treatment of pancreatic carcinoma
- Utilize appropriate supportive cancer care options in the era of targeted therapy